Keywords: sanofi-aventis, 4th-qtr, adjusted, net, leaps, older, drug
Sanofi-Aventis' 4th-qtr adjusted net leaps 13,9%, on older drug sales growth
Article | 16 February 2009
Sanofi-Aventis' new chief executive, Chris Viehbacher, gave an upbeat presentation of the French drug major's fourth-quarter and full-year 2008 results, stressing ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
